Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Adds High Content Screening In Vitro Micronucleus Test

 

High Content Screening Approach Improves Early Genotoxicity Detection

Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces that it has added to its service portfolio an automated, high content screening (HCS) implementation of the in vitro micronucleus test for detection of genotoxicity. This approach improves the accuracy and cost-effectiveness of early-stage genotoxicity testing over existing assay methods.

The micronucleus test identifies genotoxic carcinogens, i.e., carcinogens that act by causing damage to DNA. During cell division, if a chromosome or a fragment of a chromosome fails to be incorporated into one of the daughter nuclei – typically as a consequence of genetic damage – the chromosome may form its own micronucleus. This micronucleus can be detected using HCS techniques.  

Using HCS to detect these micronuclei has several advantages over traditional manual methods, the most important of which is that it improves accuracy and reliability because it allows automated scoring and an increase in statistical power through HCS’s ability to rapidly and automatically measure effects on large numbers of cells. The automation also allows large volumes of compounds to be screened faster, to accommodate early discovery needs.

To learn more about Cyprotex's HCS services, please click here.

Over the last decade the Organization for Economic Cooperation and Development (OECD) has established guidelines for the micronucleus test. Validation by European Center for the validation of Alternative Methods (ECVAM), an organisation that promotes the scientific and regulatory acceptance of non-animal tests of importance to biomedical sciences, led to the in vitro micronucleus test being accepted as a scientifically valid alternative to the in vitro chromosome aberration assay for genotoxicity testing. Cyprotex’s fully automated assay design has been developed following these guidelines.

Dr. Katya Tsaioun, Cyprotex’s Chief Scientific Officer, comments on the launch of this improved assay: “Drug, cosmetic and agrichemical compounds still fail in late-stage development due to genotoxicity, at a tremendous cost to the industries. Consequently, as companies try to increase success rates in later stages of development, in vitro micronucleus testing, alongside other toxicity assays, is increasingly becoming a routine early-stage assay.”

Dr. Anthony Baxter, Cyprotex’s CEO, announces: “Cyprotex is pleased to support pharmaceutical, cosmetic and agrichemical companies with this improved method for identifying genotoxicity during early-stage development as part of a comprehensive de-risking strategy.”

For further information:

Cyprotex PLC
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com

Singer Capital Markets Limited (broker to Cyprotex)
Tel: +44 (0) 203 205 7500
Shaun Dobson
shaun.dobson@singercm.com
Claes Spang
claes.spang@singercm.com
www.singercm.com

FTI Consulting
Tel: +44 (0) 20 7831 3113
Ben Brewerton
Ben Atwell
Mo Noonan
cyprotex@fticonsulting.com
www.fticonsulting.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close